Track topics on Twitter Track topics that are important to you
Catalent said today it has agreed to acquire Juniper Pharmaceuticals for $133 million, in a deal that adds a U.K. center of excellence for early drug development to similar centers that the buyer established on the West Coast and plans to create on the East Coast. The acquisition continues the consolidation of contract development and manufacturing organizations (CDMOs) worldwide—a consolidation that included Catalent’s $950 million purchase of Cook Pharmica late last year. Juniper’s operations include Juniper Pharma Services, a CDMO based in Nottingham, U.K., that focuses on fee-for-service drug formulation development and clinical trial manufacturing services. By combining Juniper Pharma Services with its own drug development and manufacturing services in the U.S. and Europe, Catalent said, the acquisition will expand and strengthen its offerings in formulation development, bioavailability solutions and clinical-scale oral dose manufacturing—as well as complement its integrated global clinical and commercial supply network. Those ...
Original Article: Catalent to Acquire Juniper, Adding Early Drug Development CapabilitiesNEXT ARTICLE
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...